Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Moderate Hepatic Impairment × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6 Melanoma 2 Disease Progression 2 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Meningioma 1 Lymphoma 1 Leukemia 1 Endometrial Neoplasms 1 Chondrosarcoma 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07343960 2026-02-24

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting

Moderate Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon ⚡